Drug Topics
FEBRUARY 5, 2024
Participants of a recent study who had pre-existing depression or anxiety were significantly more likely to develop insomnia.
PharmaVoice
FEBRUARY 5, 2024
The biotech’s bone- and muscle-building treatments could someday help humans reach other planets.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
FEBRUARY 5, 2024
As a result of an increase in adolescent inpatient visits with a sexually transmitted infection (STI) diagnosis in 2020, further work is needed to improve STI care, particularly for this demographic.
STAT
FEBRUARY 5, 2024
Johnson & Johnson faces a consequential new class action lawsuit — not in its role as a manufacturer of drugs, but as an employer and purchaser of prescription drugs for its workers. Ann Lewandowski, a health care policy and advocacy director at J&J, sued her company on Monday for allegedly overpaying its pharmacy benefit manager for its employees’ medicines, citing previous STAT reporting to support some of the allegations.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmacy Times
FEBRUARY 5, 2024
The study authors note that to effectively implement tools, processes, and strategies within practices, the stigma surrounding cognitive impairment must be addressed.
STAT
FEBRUARY 5, 2024
Amgen is trying a unique strategy with its obesity drug candidate: testing whether it can wean patients toward lower or less frequent doses over time. Very early data hints that Amgen’s candidate, called MariTide, may provide longer-lasting weight loss than highly popular obesity drugs on the market like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
STAT
FEBRUARY 5, 2024
Katie Keim was diagnosed with type 1 diabetes in 1967 when she was eight, well before the era of insulin pumps or even reliable home testing. The condition started eating away at her vision 20 years later. By the time she was 36, her sight was completely gone. Keim had lived an independent life as a child despite her illness. Her summers were spent exploring oceans with her family, not at diabetic summer camps.
PharmaVoice
FEBRUARY 5, 2024
Patent thickets are the latest target in lawmakers' bid to lower drug prices.
STAT
FEBRUARY 5, 2024
After a months-long fight with Texas Medicaid over coverage of a gene therapy, Afghan refugees now have a chance to save their infant son. After initially balking , Texas officials have agreed to pay for the costly treatment, the boy’s family and his doctor told STAT. At the end of last week, N. Pashai’s cell phone rang. It was from a Minnesota area code.
pharmaphorum
FEBRUARY 5, 2024
Data science in healthcare is transforming the industry, from drug discovery to patient care. Learn about the role of data, artificial intelligence (AI), and the impact of initiatives like the NHS Datastore in revolutionising healthcare outcomes.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
FEBRUARY 5, 2024
LONDON — The investment arm of Novo Nordisk’s parent foundation is buying drug manufacturer Catalent in a $16.5 billion deal, an acquisition that will give Novo additional sites as it builds up production of its booming obesity and diabetes drugs. Under the deal, Novo Holdings is purchasing Catalent, a major contract development and manufacturing company with more than 50 sites globally.
Fierce Healthcare
FEBRUARY 5, 2024
Rural providers optimistic about financial stability, plan to expand services, Wipfli survey finds agliadkovskaya Mon, 02/05/2024 - 15:34
STAT
FEBRUARY 5, 2024
At the end of each chapter in “Rebel Health: A Field Guide to the Patient-Led Revolution in Medical Care,” there’s a box. It summarizes the chapter, distilling what a reader just encountered into easy-to-digest bullet points. The author, Susannah Fox, admits she stole that idea from “The Long Covid Survival Guide,” which was written by patients for patients.
Pharmacy Times
FEBRUARY 5, 2024
In December 2023, the FDA granted expanded indications for bempedoic acid and bempedoic acid plus ezetimibe in the treatment of primary hyperlipidemia.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
STAT
FEBRUARY 5, 2024
WASHINGTON — Two Republican lawmakers who introduced legislation to water down the Inflation Reduction Act’s Medicare drug price negotiation program managed to find themselves a Democratic co-sponsor — even though every single Democrat in Congress in 2022 voted for the legislation. They found their perfect candidate in Rep. Don Davis, a Democrat representing a North Carolina district that includes parts of the state’s Research Triangle.
pharmaphorum
FEBRUARY 5, 2024
A bladder cancer study prompts Astellas to lift peak sales prediction for Padcev, although its menopause therapy Veozah isn’t ramping up as hoped.
STAT
FEBRUARY 5, 2024
Devoted Health has been one of the most prominent health insurance and provider startups of the past decade — founded and overseen by several alumni of former President Barack Obama’s administration. But it has not turned a profit after five years of selling Medicare Advantage plans to older adults, according to a STAT analysis of Devoted’s financial filings.
Fierce Healthcare
FEBRUARY 5, 2024
Cano Health today announced its intentions for file for bankruptcy in an effort to stay afloat after incurring nearly $1 billion in debt. | Cano said that it has secured a $150 million commitment in debtor-in-possession financing from some of its lenders, which is subject to court approval.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
STAT
FEBRUARY 5, 2024
Starting this year, private Medicare plans have to cover their members’ hospitalizations at the higher inpatient rate if their doctors predict they’ll have to stay beyond two midnights. It’s the same rule — appropriately called the two-midnight rule — that traditional Medicare has followed for a decade. After it came out that Medicare Advantage plans were routinely denying coverage for necessary services , the federal government decided they ought to be held to
Fierce Pharma
FEBRUARY 5, 2024
Less than two months after the FDA approved the combination treatment of Astellas and Pfizer’s Padcev and Merck’s Keytruda in first-line bladder cancer, the Japanese company has
STAT
FEBRUARY 5, 2024
Novartis said late Monday it has agreed to buy German biotech MorphoSys and its pipeline of cancer drugs for 2.7 billion euros, or $2.9 billion. The Swiss drugmaker will pay 68 euros, or around $73, per share, nearly twice Morphosys’s average trading price over the last month. At the center of the deal is pelabresib, a blood cancer pill that in November posted mixed results in a Phase 3 trial.
Drug Store News
FEBRUARY 5, 2024
Is the retailer still the hip, trendsetting option for beauty and wellness discovery among consumers?
STAT
FEBRUARY 5, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we talk about two players that want to join the obesity market with updates to the GLP-1 class: Amgen and Regeneron. Also, a draft bill in Congress would restrict U.S. involvement with Chinese biotechs.
Fierce Pharma
FEBRUARY 5, 2024
After leading Novartis and Roche through pivotal years in 2023, the CEOs of the Swiss drug giants each netted multimillion-dollar compensation packages. | After leading Swiss drug giants Novartis and Roche through pivotal years, their CEOs have each netted multimillion-dollar compensation packages for 2023.
STAT
FEBRUARY 5, 2024
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of phone calls, online meetings, and deadlines has predictably returned. But you knew this would happen. After all, the world keeps spinning, at least for now. So time to give it a nudge in a better direction with a cup of delicious stimulation.
Pharmacy Times
FEBRUARY 5, 2024
Switching from adalimumab originator to SB5 did not cause clinically significant differences in treatment efficacy and safety for patients with noninfectious uveitis.
pharmaphorum
FEBRUARY 5, 2024
Better-than-expected sales of some of its new products, including Skyrizi and Rinvoq, helped AbbVie handle a sharp decline in sales of former cash-cow product Humira in the last quarter of 2023.
The Checkup by Singlecare
FEBRUARY 5, 2024
If your healthcare provider has recently expressed concern about your cholesterol levels, you’re not alone. About 86 million American adults have high cholesterol. Though high cholesterol does not usually cause symptoms, it can lead to high blood pressure, heart disease, stroke, and heart attack if left untreated. Fortunately, lifestyle changes—diet, in particular—can help you lower your cholesterol naturally. 10 home remedies for high cholesterol Along with a personalized action plan from a hea
pharmaphorum
FEBRUARY 5, 2024
4D Molecular Therapeutics' 4D-150 gene therapy for wet AMD has shown efficacy and a reduced need for eye injections with current therapy Eylea in a phase 2 trial.
Drug Store News
FEBRUARY 5, 2024
The retailer also is holding additional events to promote healthy lifestyles.
pharmaphorum
FEBRUARY 5, 2024
Novo Nordisk has taken the bold step of buying three manufacturing facilities from contract development and manufacturing organisation Catalent as it tries to meet surging demand for its diabetes and obesity drugs. The deal includes $11 billion upfront to buy the fill-finish sites that Novo Nordisk said will enable “an expansion of the manufacturing capacity at scale and speed while providing future optionality and flexibility for Novo Nordisk’s existing supply network.
Outsourcing Pharma
FEBRUARY 5, 2024
No new treatments to combat the major public health issue of alcohol use disorder (AUD), have been brought to market for ten years - and with half of heavy drinkers refusing the abstinence route, new drug could be the answer.
STAT
FEBRUARY 5, 2024
More than half of the injector-pen patents for several widely used diabetes treatments — including Ozempic and Mounjaro — do not mention several important characteristics that should otherwise prevent them from being listed in a key federal registry, according to a new analysis. As a result, the researchers contend the patents may be unfairly used to preclude competition from companies that may want to market lower-cost generic products.
Expert insights. Personalized for you.
281 
Let's personalize your content